IPO and growth Sun BioPharma recently went public and is aiming to raise funds via an IPO, indicating a growth trajectory and increased investor scrutiny. Sales opportunities may stem from partnerships, contract research, clinical development services, and supply chain collaborations to support expansion.

Pancreatic cancer focus The company concentrates on developing SBP-101 for pancreatic cancer, including metastatic PDA in combination regimens. This specialization creates opportunities for targeted partnerships, diagnostics, translational research, and early-access or compassionate-use programs with oncologists and hospital systems.

Leadership transitions New CEO appointment alongside ongoing involvement of the founder signals strategic pivots and potential shifts in R&D priorities and partnerships. Engage to align value propositions with leadership’s vision, including collaboration on clinical milestones and strategic alliances.

Clinical stage readiness As a clinical-stage biotech with a modest team and substantial funding history, there is likely demand for CRO/CMO support, manufacturing scale-up planning, regulatory consulting, and patient access strategies to advance SBP-101 through trials.

Operational tech footprint Adoption of industry-standard tech such as SAS, Siemens Opcenter, and Smartsheet suggests established operations and data workflows. This can be leveraged to propose integrated EPM, data analytics, supply chain optimization, and digital collaboration services to accelerate development timelines.